Sethera Therapeutics Appoints Biotech Pioneer Dr. Robert Langer to Head and Chair the Scientific Advisory Board and Brigadier General Larry Lunt to Board of Directors

Salt Lake City, Utah--(Newsfile Corp. - February 5, 2025) - Sethera Therapeutics announced the appointment of Dr. Robert Langer, a world-renowned scientist, entrepreneur, and co-founder of Moderna, to Head and Chair its Scientific Advisory Board. The company also welcomed Brigadier General Larry V. Lunt, USAF (Ret.), a distinguished leader with decades of strategic expertise, to its Board of Directors.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Scientific Leadership: Dr. Langer's expertise in drug delivery systems and tissue engineering will be invaluable in guiding Sethera's scientific strategy and advancing its pipeline of innovative peptide-based therapeutics.
• Strategic Leadership: Brig. Gen. Lunt's strategic vision and proven ability to lead organizations through complex challenges will be essential as Sethera continues to grow and evolve.
• Company's Position Strengthened: The addition of Dr. Langer and Brig. Gen. Lunt to Sethera's leadership team strengthens the company's position in the field of peptide therapeutics. With a focus on accessing complex molecular architectures, Sethera is developing therapies for a wide range of diseases and is poised to make significant contributions to the advancement of human health.

Click image above to view full announcement.

About Sethera Therapeutics

Sethera Therapeutics is a privately held biopharmaceutical company dedicated to transforming the field of peptide therapeutics. The company's proprietary platform technology enables the development of enzymatically-altered peptide-based therapies with enhanced efficacy, safety, and delivery. The Sethera platform potentially targets a wide range of therapeutic areas. Sethera is building a world-class team and is committed to advancing the field of peptide therapeutics and improving the lives of patients worldwide.

Source: Sethera Therapeutics

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239712